As the primary action of the GG constituent glycyrrhizin is to inhibit 11betaHSD2 and (directly or indirectly) TLR4, this principal may emerge as a new target for a definable subgroup of patients with depression, if confirmed in future research. Here, HSD11B2 is linked to depressive symptom measurement.